Eisai's Commitment To Oncology Demonstrated By Clinical Data To Be Presented At ASCO Annual Meeting

LONDON, May 16 /PRNewswire/ -- Eisai Europe Ltd announced today that results from 9 clinical data abstracts about compounds in the company's oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicag

Related Keywords

London ,City Of ,United Kingdom ,United States ,Chicago ,Illinois ,American ,Mesylate ,Haruo Naito ,Prnewswire Eisai Europe Ltd ,Ligand Pharmaceuticals ,Eisai Co ,Eisai Europe Ltd ,A Foundation Merit Award ,Eisai Co Ltd ,Morphotek Inc ,Europe Ltd ,Annual Meeting ,American Society ,Clinical Oncology ,Monoclonal Antibody ,Folate Receptor Alpha ,Sensitive Ovarian Cancer ,Vista Room ,Lobby Poster ,Phasei Study ,Humanized May ,Antibody Against Folate Receptor ,Advanced Epithelial Ovarian ,Rat Models ,Monoclonal June ,Eribulin June ,Locally Advanced ,Metastatic Breast Cancer Location ,Capecitabine Therapy Poster ,Advanced Breast Oncologist ,Patient Roles ,Cancer Assessing Current ,Metastatic Breast ,Eisai Europe ,Andrew Day ,Communications Director ,Cancer Research ,